A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Review expert faculty discussion of BTK inhibitor resistance in CLL including optimal testing and treatment sequencing to overcome resistance to prior therapy

  • Provider:Clinical Care Options
  • Activity Link: https://clinicaloptions.com/CE-CME/hematology/btki-resistance-in-cll-3/28307-53802
  • Start Date: 2024-10-01 05:00:00
  • End Date: 2024-10-01 05:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
  • Commercial Support: Source: AstraZeneca (Any division) - Amount: 150000.0 - Is Kind Support: False
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Knowledge, Learner/Team Competence
  • Provider Ship: Directly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.